Hair Regeneration in Menopausal and Androgenetic Alopecia Patients Using PTT-6® Exosomal Proteins

Abstract

Hair thinning and loss are frequently reported symptoms during the perimenopausal and postmenopausal stages, contributing to significant psychological distress among affected women. Current non-surgical interventions offer limited efficacy, often failing to meet patient expectations. PTT-6®, a proprietary extract of exosomal proteins derived from umbilical cord lining mesenchymal stem cells, has emerged as a novel regenerative approach for hair restoration. This study evaluates the efficacy and tolerability of PTT-6® in women experiencing menopausal and androgenetic hair loss.

Twelve female patients (aged 37–54) presenting with early-stage hair thinning were treated over a 12-week period with a combination protocol involving an in-clinic microneedling session followed by weekly applications at home. Improvements in hair density, reduction in shedding, and patient satisfaction were evaluated at 6 and 12 weeks. The majority of patients reported subjective improvements, which were corroborated by photographic documentation. No adverse effects were reported. While limited by small sample size and reliance on self-assessment tools, the results suggest that PTT-6® may offer a safe and promising solution for menopausal and female-pattern hair loss. Larger, controlled studies are warranted.

Introduction

Hair loss is a prevalent but underrecognized concern among menopausal women, often resulting in diminished self-esteem and psychological distress. Estimates suggest that over 50% of women will experience some degree of hair thinning or loss by the age of 50, frequently exacerbated during and after menopause due to the decline in oestrogen and progesterone levels. This hormonal shift alters the hair cycle, shortening the anagen (growth) phase and leading to increased shedding and miniaturization of follicles.

The aesthetic and psychological consequences of menopausal hair loss are profound. Affected women often report feelings of embarrassment, loss of femininity, and social withdrawal. These emotional burdens can be compounded by the lack of effective treatment options, especially those that are non-invasive, natural, and appropriate for long-term use. 

Current therapies for female-pattern hair loss include minoxidil, low-level laser therapy, and off-label use of oral anti-androgens. However, these treatments often yield modest results and undesirable side effects. This has spurred interest in regenerative therapies, including the use of stem cell-derived exosomal proteins, which offer a clean, cell-free, and growth-factor-rich alternative for hair follicle rejuvenation. 

PTT-6® is a topical formulation rich in exosomal proteins extracted from ethically derived mesenchymal stem cells from red deer umbilical cord lining. These proteins play critical roles in modulating inflammation, enhancing cellular communication, and stimulating follicular stem cells. This study aims to assess the efficacy and safety of PTT-6® when used in conjunction with microneedling in women suffering from menopausal hair loss and androgenetic alopecia.

Materials and Methods

A total of 12 female patients aged 37 to 54 years, all presenting with menopausal or androgenetic hair loss (Ludwig scale I–II), were enrolled in a study conducted at Time Clinic, London. Exclusion criteria included active scalp disease, recent use of oral or topical hair growth medications, and pregnancy.

Each patient underwent an in-clinic microneedling session using a 1.25mm stamp device to enhance delivery of PTT-6®. This was followed by five weeks of home treatment involving a 0.5mm microneedling stamp and topical application of PTT-6® serum, applied once weekly. Patients were instructed on correct home use and monitored for compliance.

Assessments were conducted at 6 and 12 weeks. Evaluation methods included high-resolution digital photography, patient self-assessment questionnaires, and qualitative feedback regarding hair density, reduction in shedding, and overall satisfaction. A total of 10 patients completed the 6-week assessment, and a total of 8 patients completed the full 12-week study.

Results

By week 6, 9 out of 10 participants reported noticeable improvements, including decreased daily hair shedding, improved thickness of the hair and enhanced volume at the hairline and temples. Photographic evidence demonstrated visible improvements in hair density, particularly in areas of diffuse thinning. Several patients also noted unprompted positive remarks from peers and family, adding to their perceived treatment efficacy.

At the 12-week mark, all patients showed mild to definitive improvement in hair growth and thickness. No adverse events were reported, and the treatment was well-tolerated by all participants, including those with sensitive skin.